“Imbruvica totaled revenue of $3.3 billion an increase of $200 million reflecting higher persistency rates for existing patients.”

In context

“imate for acquired IPR&D expense that may be incurred beyond the third quarter. We now expect total net revenues of approximately $56 billion, an increase of $500 million. At current rates, we expect foreign exchange to have a 0.7% unfavorable impact on full-year sales growth. This revenue forecast includes the following updates to select key products and therapeutic areas. We now approximate Skyrizi global sales of $11.5 billion, an increase of $500 million due to continued strong performance across all approved indications. Rinvoq total revenue of $5.8 billion an increase of $100 million reflecting robust uptake in IBD. U.S. Humira total sales of $7.4 billion a decrease of $400 million reflecting more Humira molecule volume moving to other novel mechanisms, including Skyrizi and Rinvoq. Imbruvica totaled revenue of $3.3 billion an increase of $200 million reflecting higher persistency rates for existing patients. Venclexta total sales of $2.6 billion an increase of $100 million reflecting momentum in both U.S. and international markets. Aesthetics global revenue of $5.3 billion a decrease of $200 million almost entirely due to lower Juvederm volume which continues to be impacted by challenging economic conditions in key markets. Vraylar total sales of $3.3 billion a decrease of $100 million reflecting continued strong prescription demand partially offset by modestly unfavorable channel mix. And for Botox, we now expect global revenue in the therapeutic space of $3.3 billion an increase of $100 million reflecting robust demand across all indications. Moving to the P&L for 2024. We continue to forecast a full-year adjusted gross margin of approximately 84% of sales, adjusted R&D investment of 14%, a”